UNIVERSITY OF MASSACHUSETTS Patent applications |
Patent application number | Title | Published |
20160135438 | ISOLATION OF NOVEL AAV'S AND USES THEREOF - The invention in some aspects relates to isolated nucleic acids, compositions, and kits useful for identifying adeno-associated viruses in cells. In some aspects, the invention provides kits and methods for producing somatic transgenic animal models using recombinant AAV (rAAV) to an animal having at least one transgene that expresses a small interfering nucleic acid or at least one binding site for a miRNA. | 05-19-2016 |
20160102804 | DEVICES FOR APPLICATION AND LOAD BEARING AND METHOD OF USING THE SAME - Gecko-like adhesive application devices suited for dynamic applications are disclosed, where the device can be easily applied to target substrates, exhibiting a firm hold, and subsequently released therefrom. Gecko-like adhesive application devices that are suited for sustained holding after easy application (e.g., on vertical or inclined surfaces or ceiling) also are disclosed. | 04-14-2016 |
20150322167 | ANTI-SOD1 ANTIBODIES AND USES THEREOF - The present invention features anti-SOD1 antibodies and methods of using the antibodies for the treatment of amyotrophic lateral sclerosis (ALS) or the amelioration of symptoms associated with ALS. | 11-12-2015 |
20150313881 | Therapeutic Methods for Type I Diabetes - The invention relates to the treatment and prevention of type I diabetes. More specifically, the invention relates to compounds that treat or prevent the body's immune system from destroying β-cells (i.e., insulin-producing cells in the pancreatic islets of Langerhans) by inhibition of JNK2, selective inhibition of JNK2, or inhibition of the expression of the MAPK9 gene or gene product. In one embodiment, the present invention contemplates the diagnosis, identification, production, and use of compounds which modulate MAPK9 gene expression or the activity of the MAPK9 gene product including but not limited to, JNK2, the nucleic acid encoding MAPK9 and homologues, analogues, and deletions thereof, as well as antisense, ribozyme, triple helix, antibody, and polypeptide molecules as well as small inorganic molecules. The present invention contemplates a variety of pharmaceutical formulations and routes of administration for such compounds. | 11-05-2015 |
20150240232 | Deducing Exon Connectivity by RNA-Templated DNA Ligation/Sequencing - A technology is described that is capable of generating high-throughput sequencing (HTS) read length DNA products to accurately and reliably provide exon connectivity information for alternatively spliced isoforms. The method is not limited by the initial size of the isoform as the technology removes the template oligonucleotide sequence and a newly formed full length ligated product provides an HTS-compatible read length sequence that comprises information that corresponds to the consecutive order of the exons in the original template oligonucleotide. | 08-27-2015 |
20150224538 | METHOD FOR PRODUCING A FILM HAVING A NANO-STRUCTURE ON THE SURFACE OF THE FILM - The present invention provides a method for producing easily a membrane (film) having a micro surface structure (porous structure, fibrous structure and the like) in nano-order. The present invention comprises a method for producing a film having a nano-structure on the surface of the film, comprising the steps of (1) coating a substrate with a solution containing a copolymer including two or more homopolymer segments and an organic solvent having boiling point of 82° C. or more and dielectric constant of 30 or less to form a membrane, (2) providing the membrane with a water vapor-containing gas having relative humidity of 50% or more to age the membrane, and (3) drying the membrane to obtain the film. | 08-13-2015 |
20150220700 | METHODS AND DEVICES FOR DETERMINING OPTIMAL AGENT DOSAGES - The present invention is generally directed to methods and devices for determining dosing for a medical agent. In some embodiments, a mathematical algorithm is employed for computing erythropoiesis-stimulating agents dosing for treating anemia in a subject, e.g., a human subject. Any suitable dosing may be used, e.g., intravenous, subcutaneous, or oral dosing. In some cases, dosing for a wide range of subject types and health conditions can be achieved using the devices and methods disclosed herein. | 08-06-2015 |
20150209447 | CROSSLINKED POLYMER NANO-ASSEMBLIES AND USES THEREOF - The invention provides powerful methods and compositions for designing, selecting, fine-tuning and optimizing polymer nanogel and other supramolecular assemblies for various properties including, for example, particle size, density and morphology, guest loading capacity and encapsulation stability, and dynamic release control. | 07-30-2015 |
20150198585 | METHODS, COMPOSITIONS AND KITS FOR ASSAYING MITOCHONDRIAL FUNCTION - The invention provides methods, compositions, devices, and kits relating to the use of cholesterol-dependent cytolysins (e.g., PFOs) for measuring intracellular mitochondrial activity. | 07-16-2015 |
20150191744 | CAS9 EFFECTOR-MEDIATED REGULATION OF TRANSCRIPTION, DIFFERENTIATION AND GENE EDITING/LABELING - The present disclosure relates to methods of and systems for modifying the transcriptional regulation of stem or progenitor cells to promote their differentiation or reprogramming of somatic cells. Further, the labeling and editing of human genomic loci in live cells with three orthogonal CRISPR/Cas9 components allow multicolor detection of genomic loci with high spatial resolution, which provides an avenue for barcoding elements of the human genome in the living state. | 07-09-2015 |
20150133318 | ENZYMATIC METHOD TO ENRICH FOR CAPPED RNA, KITS FOR PERFORMING SAME, AND COMPOSITIONS DERIVED THEREFROM - The instant invention is based, at least in part, on the identification of novel methods for the enzymatic enrichment of capped RNAs. The invention provides, e.g., methods for enrichment of capped RNAs, kits for making such capped RNAs, and compositions of enriched RNAs or cDNA libraries derived therefrom. | 05-14-2015 |
20150111947 | COMPOSITIONS AND METHODS FOR DECREASING LEUKOCYTE EXTRAVASATION AND VESSEL FLUID LEAKAGE - Provided herein are methods of decreasing leukocyte extravasation from a lymph or blood vessel into a tissue in a mammal, methods of decreasing fluid leakage from a lymph or blood vessel in a mammal in need thereof, methods of decreasing formation of atherosclerotic plaques in a mammal in need thereof, and methods of treating atherosclerosis in a mammal that include administering to the mammal an oligonucleotide that decreases Mitogen-activated protein kinase kinase kinase kinase 4 (Map4k4) mRNA expression in an endothelial cell. Also provided are methods of identifying a candidate agent useful for decreasing leukocyte extravasation or decreasing fluid leakage from a lymph or blood vessel in a mammal, and compositions containing an oligonucleotide that decreases Map4k4 mRNA expression in an endothelial cell and additional therapeutic agents. | 04-23-2015 |
20150105525 | POLYMERIZATION INITIATING SYSTEM AND METHOD TO PRODUCE HIGHLY REACTIVE OLEFIN FUNCTIONAL POLYMERS - A method for producing highly reactive olefin polymers wherein at least 50 mol. % of the polymer chains have terminal double bonds, and a novel polymerization initiating system for accomplishing same. | 04-16-2015 |
20150080242 | NANOPORE SENSORS AND USES THEREOF - Aspects of the invention relate to nanopores useful as sensors for detecting intermolecular interactions. | 03-19-2015 |
20150031738 | CYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME - The present invention provides compounds, or pharmaceutically acceptable salts thereof, for inhibiting the growth of a microbe; treating a mammal having a microbial infection, mucositis, an ophthalmic infection, an otic infection, a cancer, or a | 01-29-2015 |
20140373188 | COMPOSITIONS FOR RNA INTERFERENCE AND METHODS OF USE THEREOF - The present invention provides compositions for RNA interference and methods of use thereof. In particular, the invention provides single-stranded small interfering RNAs. Functional and genomic and proteomic methods are featured. Therapeutic methods are also featured. | 12-18-2014 |
20140370597 | RNA INTERFERENCE FOR THE TREATMENT OF GAIN-OF-FUNCTION DISORDERS - The present invention relates to the discovery of an effective treatment for a variety of gain-of-function diseases, in particular, Huntington's disease (HD). The present invention utilizes RNA Interference technology (RNAi) against polymorphic regions in the genes encoding various gain-of-function mutant proteins resulting in an effective treatment for the gain-of-function disease. | 12-18-2014 |
20140352881 | DOUBLE- AND MULTI-SIDED ADHESIVE DEVICES - The invention provides unique releasable adhesive devices and related methods that are capable of simultaneously adhering to two or multiple target surfaces of various nature and allow high load capacity, are reusable, easy release and suitable for extended and repeated use. | 12-04-2014 |
20140350083 | Genetic Inhibition by Double-Stranded RNA - A process is provided of introducing an RNA into a living cell to inhibit gene expression of a target gene in that cell. The process may be practiced ex vivo or in vivo. The RNA has a region with double-stranded structure. Inhibition is sequence-specific in that the nucleotide sequences of the duplex region of the RNA and of a portion of the target gene are identical. The present invention is distinguished from prior art interference in gene expression by antisense or triple-strand methods. | 11-27-2014 |
20140350066 | COMPOSITIONS AND THEIR USES FOR GENE THERAPY OF BONE CONDITIONS - In certain preferred embodiments, the present invention provides compositions and methods for the treatment of bone conditions associated with low bone density. In preferred embodiments, the present invention provides compositions and methods for the treatment of osteoprotegerin-responsive conditions. | 11-27-2014 |
20140341809 | High-Affinity DMF5 T Cell Receptor (TCR) Variants - High-affinity variants of the DMF5 TCR, and methods of use thereof for the treatment and imaging of cancer in a patient. | 11-20-2014 |
20140335054 | CNS TARGETING AAV VECTORS AND METHODS OF USE THEREOF - The invention in some aspects relates to recombinant adeno-associated viruses useful for targeting transgenes to CNS tissue, and compositions comprising the same, and methods of use thereof. In some aspects, the invention provides methods and compositions for treating CNS-related disorders. | 11-13-2014 |
20140335047 | DRUG DELIVERY PRODUCT AND METHODS - The present invention provides a particulate delivery system comprising an extracted yeast cell wall comprising beta-glucan, a payload molecule and a payload trapping molecule. The invention further provides methods of making and methods of using the particulate delivery system. | 11-13-2014 |
20140323483 | TYPE III SECRETION INHIBITORS, ANALOGS AND USES THEREOF - The invention, in some aspects, relates to compounds and compositions useful for inhibiting Type III secretion systems in pathogenic bacteria, such as | 10-30-2014 |
20140314836 | Modulation of Midbody Derivatives - The number of midbody derivatives in a cell may be modulated by modulating autophagy induced by NBR1. Exemplary methods include modulating the amount or activity of NBR1 in the cell, potentiating or inhibiting binding between NBR1 and Cep55 in the cell, or modulating the amount of Cep55 in the cell. These methods can be used in the treatment of cancers or in methods of reprogramming cells. | 10-23-2014 |
20140303458 | SYSTEMS AND METHODS FOR INHIBITING APNEIC EVENTS - Systems and methods are disclosed to monitor physiological for the occurrence of life threatening events and to apply stimulation to prevent the occurrence of said life-threatening events. Systems and methods for applying the stimulation are also disclosed. These systems include applying the stimulation through via a mattress having a passive section and an active section, a plurality of focal stimulators, and/or an array to apply the stimulation are also disclosed. These devices include a mattress with an active region and a passive region, a stimulating array do deliver targeted stimulation, and a plurality of stimulators to apply focused stimulation. | 10-09-2014 |
20140296600 | PRODUCTION OF PARA-XYLENE BY CATALYTICALLY REACTING 2,5-DIMETHYLFURAN AND ETHYLENE IN A SOLVENT - The present invention provides a renewable route to para-xylene via cycloaddition of ethylene and 2,5-dimethylfuran and subsequent dehydration with high selectivity and high yields using acidic heterogeneous catalysts and a solvent for 2,5-dimethylfuran. The use of a solvent shows significant effects in the reduction of competing side reactions including hydrolysis of 2,5-dimethylfuran to 2,5-hexanedione, alkylation of p-xylene, and polymerization of 2,5-hexanedione. | 10-02-2014 |
20140296486 | NOVEL AAV'S AND USES THEREOF - The invention in some aspects relates to recombinant adeno-associated viruses having distinct tissue targeting capabilities. In some aspects, the invention relates to gene transfer methods using the recombinant adeno-associate viruses. In some aspects, the invention relates to isolated AAV capsid proteins and isolated nucleic acids encoding the same. | 10-02-2014 |
20140296219 | COMPOUNDS FOR MODULATING TLR2 - The present invention is directed to methods, kits, and uses of inhibitors of LCMV mediated NF-κB activation to treat viral infections and inflammatory conditions. | 10-02-2014 |
20140294785 | DOSAGE COMPENSATING TRANSGENES AND CELLS - Methods and compositions for reducing expression of genes on Chromosome 21 (“Chr 21”) by targeting an XIST transgene to the Dual specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A) gene or a Regulator of calcineurin 1 (RCAN1) gene, and cells and transgenic animals comprising an XIST transgene inserted into a DYRK1A or RCAN1 allele, e.g., cells and animals trisomic for human Chr 21 and mouse Chr 16. | 10-02-2014 |
20140287491 | METHODS AND COMPOSITIONS FOR ENHANCING THE EFFICACY AND SPECIFICITY OF SINGLE AND DOUBLE BLUNT-ENDED siRNA - The present invention provides methods of enhancing the efficacy and specificity of RNAi using single or double blunt-ended siRNA. The invention also provides single and double-blunt ended siRNA compositions, vectors, and transgenes containing the same for mediating silencing of a target gene. Therapeutic methods are also featured. | 09-25-2014 |
20140275526 | SULFONATE COMPOUNDS - This disclosure relates to compounds containing a fluorophore covalently bonded to at least one protected sulfonate group of formula (I): | 09-18-2014 |
20140275453 | POLYMERIZATION INITIATING SYSTEM AND METHOD TO PRODUCE HIGHLY REACTIVE OLEFIN FUNCTIONAL POLYMERS - A method for producing highly reactive olefin polymers wherein at least 50 mol. % of the polymer chains have terminal double bonds, and a novel polymerization initiating system for accomplishing same. | 09-18-2014 |
20140275417 | ORGANOBORONATE NANOPARTICLES AND METHODS OF USING THE SAME - In various embodiments, the present invention provides an organoboronate nanoparticle. The nanoparticle includes a polymer, which includes a repeating unit that includes at least one organoboronate functional group. Various embodiments provide compositions including the nanoparticles, surface functionalized nanoparticles, nanoparticles including an encapsulant, methods of making the nanoparticles, and methods of using the nanoparticles, such as methods of stimuli-responsive release of encapsulants. | 09-18-2014 |
20140274962 | METHODS OF INHIBITING PRESBYOPIA - Described herein are methods of inhibiting or reversing the progression of presbyopia in an eye by administering a β | 09-18-2014 |
20140220052 | COMPOSITIONS AND METHODS FOR WOUND HEALING, AND FOR RECRUITMENT AND ACTIVATION OF MACROPHAGES IN INJURED TISSUES AND IN IMPLANTED BIOMATERIALS USED FOR TISSUE ENGINEERING - The present invention is related to the field of wound healing or tissue regeneration due to disease (i.e., for example, cardiovascular diseases, osetoarthritic diseases, or diabetes) and to healing of internal injuries. In particular, the present invention provides compositions and methods comprising molecules and nanoparticles with linked α-gal epitopes for induction of recruitment and activation of macrophages localized within or surrounding damaged and/or injured tissue. The recruited macrophages further recruit stem cells into the injured tissues. The recruited macrophages and stem cells promote the repair and regeneration of the treated injured tissue. In some embodiments, the present invention provides treatments for tissue repair in normal subjects and in subjects having impaired healing capabilities, such as diabetic and aged subjects. In some embodiments, the present invention provides treatments for injured tissues such as brain, peripheral nerve, heart muscle, skeletal muscle, lung, cartilage, bone, gastrointestinal tract and dysfunctional endocrine tissues. The invention further provides methods and compositions comprising molecules and nanoparticles with linked α-gal epitopes for inducing recruitment and activation of macrophages into biomaterial implants for improving the conversion of such implants into functional tissues and organs within treated patients. | 08-07-2014 |
20140219950 | ENHANCED TRANSPORT USING MEMBRANE DISRUPTIVE AGENTS - Compositions and methods for transport or release of therapeutic and diagnostic agents or metabolites or other analytes from cells, compartments within cells, or through cell layers or barriers are described. The compositions include a membrane barrier transport enhancing agent and are usually administered in combination with an enhancer and/or exposure to stimuli to effect disruption or altered permeability, transport or release. In a preferred embodiment, the compositions include compounds which disrupt endosomal membranes in response to the low pH in the endosomes but which are relatively inactive toward cell membranes, coupled directly or indirectly to a therapeutic or diagnostic agent. Other disruptive agents can also be used, responsive to stimuli and/or enhancers other than pH, such as light, electrical stimuli, electromagnetic stimuli, ultrasound, temperature, or combinations thereof. The compounds can be coupled by ionic, covalent or H bonds to an agent to be delivered or to a ligand which forms a complex with the agent to be delivered. Agents to be delivered can be therapeutic and/or diagnostic agents. Treatments which enhance delivery such as ultrasound, iontophoresis, and/or electrophoresis can also be used with the disrupting agents. | 08-07-2014 |
20140213475 | METHODS OF DIAGNOSING CANCER USING EPIGENETIC BIOMARKERS - The invention features methods of diagnosing cancer in a mammal (e.g., a human) by detecting a biomarker selected from a satellite II ribonucleic acid (RNA) molecule, a cancer-associated polycomb group (CAP) body, a cancer-associated satellite transcript (CAST) body, and UbH2A. Also featured is a method for identifying an agent for treating cancer in a mammal by contacting a cancer cell having a biomarker selected from a CAP body, a CAST body, and a satellite II RNA molecule with a test agent and determining whether the test agent reduces the level of the biomarker in the cancer cell. Other inventions featured are a method for determining whether a chemotherapeutic agent increases epigenetic imbalance of a cell and a method for detecting epigenetic imbalance by determining a copy number of a satellite II DNA locus at chromosome 1q12 in a cell. | 07-31-2014 |
20140201855 | MUTANT LUCIFERASES - Described are mutant luciferases, nucleic acids that encode them, cells and animals expressing them, methods of use thereof, and kits. | 07-17-2014 |
20140193340 | Luciferin Amides - This disclosure relates to luciferin amides of formula (I) shown below: | 07-10-2014 |
20140187495 | METHODS FOR TREATING GLIOBLASTOMA - Described are methods for treating cancers, e.g., glioblastoma, including administering an inhibitor of Notch signalling, e.g., a gamma secretase inhibitor, in combination with a chemotherapeutic agent. | 07-03-2014 |
20140186563 | STABILIZED POLYESTER BASED COMPOSITIONS - A polyester or polyester copolymer based composition, such as a polylactic acid based composition, is provided herein. The polyester or polyester copolymer based composition may include a plasticizer, such as an ether based, an ester based, and/or an ether-ester based plasticizer. | 07-03-2014 |
20140180677 | Analogy Finder - A user provides a query that includes at least two of a subject, a predicate, and an object. A computer system identifies synonyms of one or more of the subject, predicate, and object, and forms new queries from the identified synonyms. The system searches a dataset using the new queries, and possibly also using the user-provided query, to produce search results. The system may process the search results, such as by filtering and/or sorting them. The system provides output representing the search results to the user. The user may use the search result output to identify answers that are analogous to answers to the query originally provided by the user. | 06-26-2014 |
20140180225 | NEGATIVE PRESSURE WOUND CLOSURE DEVICE - The present invention relates to a negative pressure wound closure system and methods for using such a system. Preferred embodiments of the invention facilitate closure of the wound by preferentially contracting to provide for movement of the tissue. Preferred embodiments can utilize tissue grasping elements to apply a wound closing force to the tissue. | 06-26-2014 |
20140179760 | IN VIVO PRODUCTION OF SMALL INTERFERING RNAS THAT MEDIATE GENE SILENCING - The invention provides engineered RNA precursors that when expressed in a cell are processed by the cell to produce targeted small interfering RNAs (siRNAs) that selectively silence targeted genes (by cleaving specific mRNAs) using the cell's own RNA interference (RNAi) pathway. By introducing nucleic acid molecules that encode these engineered RNA precursors into cells in vivo with appropriate regulatory sequences, expression of the engineered RNA precursors can be selectively controlled both temporally and spatially, i.e., at particular times and/or in particular tissues, organs, or cells. | 06-26-2014 |
20140163084 | METHODS AND COMPOSITIONS FOR CONTROLLING EFFICACY OF RNA SILENCING - Based at least in part on an understanding of the mechanisms by which small RNAs (e.g., naturally-occurring miRNAs) mediate RNA silencing in plants, rules have been established for determining, for example, the degree of complementarity required between an RNAi-mediating agent and its target, i.e., whether mismatches are tolerated, the number of mismatches tolerated, the effect of the position of the mismatches, etc. Such rules are useful, in particular, in the design of improved RNAi-mediating agents which allow for more exact control of the efficacy of RNA silencing. | 06-12-2014 |
20140155569 | Flame-Retardant Derivatives - A chemical compound of structural formula (I) useful in preparation of flame retardant materials is disclosed. Homopolymer, and copolymers of a compound of formula (I), as well as methods of preparing said homo- and copolymers are also disclosed. Polymers described herein advantageous possess low heat release capacities and high char yields. | 06-05-2014 |
20140154727 | Geobacter Strains That Use Alternate Organic Compounds, Methods of Making, and Methods of Use Thereof - In preferred embodiments, the present invention provides new isolated strains of a | 06-05-2014 |
20140142161 | RAAV-BASED COMPOSITIONS AND METHODS FOR TREATING ALPHA-1 ANTI-TRYPSIN DEFICIENCIES - The invention relates to isolated nucleic acids and rAAV-based compositions, methods and kits useful for treating genetic diseases (e.g., alpha-1 antitrypsin deficiency). | 05-22-2014 |
20140142107 | ANTIFUNGAL AGENTS AND USES THEREOF - Antimicrobial agents, compositions that include the agent(s) and use(s) thereof are provided. Also disclosed are screening assays for identifying antimicrobial agents. | 05-22-2014 |
20140134203 | Respiratory Syncytial Virus (RSV) Sequences For Protein Expression and Vaccines - The invention provides RSV fusion (F) protein ectodomain polypeptide sequences and nucleotide sequences encoding them, as well as cells containing the invention's polypeptide and nucleotide sequences. The invention further provides VLPs that contain the invention's polypeptides, and methods for using the VLPs for protein expression and vaccine formulation. Also provided are methods for distinguishing between subjects immunized with the invention's compositions and subjects infected with RSV. | 05-15-2014 |
20140125676 | Feature Type Spectrum Technique - Objects in a sample set, and/or data representing those objects, are analyzed to determine whether the objects have features in a feature set. Each object may be analyzed more than once to produce multiple determinations of whether the object has features in the feature set. The frequencies with which features in the feature set are observed in the objects in the object set may be used to produce output representing the frequencies of observation. An example of such output is a bar chart representing the frequency of observation of features in the feature set in a particular object. The feature output may be used to identify one or more obscure (i.e., low frequency) features in the particular object. Various operations performed by the system may be performed by computers, humans, or a combination thereof. | 05-08-2014 |
20140120614 | ANTIBODIES AGAINST CLOSTRIDIUM DIFFICILE TOXINS AND USES THEREOF - Antibodies that specifically bind to toxins of | 05-01-2014 |
20140107123 | Therapeutic Methods For Type I Diabetes - The invention relates to the treatment and prevention of type I diabetes. More specifically, the invention relates to compounds that treat or prevent the body's immune system from destroying β-cells (i.e., insulin-producing cells in the pancreatic islets of Langerhans) by inhibition of JNK2, selective inhibition of JNK2, or inhibition of the expression of the MAPK9 gene or gene product. In one embodiment, the present invention contemplates the diagnosis, identification, production, and use of compounds which modulate MAPK9 gene expression or the activity of the MAPK9 gene product including but not limited to, JNK2, the nucleic acid encoding MAPK9 and homologues, analogues, and deletions thereof, as well as antisense, ribozyme, triple helix, antibody, and polypeptide molecules as well as small inorganic molecules. The present invention contemplates a variety of pharmaceutical formulations and routes of administration for such compounds. | 04-17-2014 |
20140100619 | ANTERIOR SPINE ARRAY CLAMP - An apparatus that connects an imaging treatment guidance system (ITGS) to a fixed location in a patient. One example of an ITGS is the Medtronic StealthStation® Treatment Guidance System used in the O-arm™ Surgical Imaging System. The apparatus is fixed relative to a patient at a proximal end, and supports the ITGS at a distal end. The apparatus has a plurality of adjustably-joined arms. In one embodiment, the proximal end of the apparatus is attached to a pin distractor fixed to the anterior spine of a patient. The apparatus provides multiplanar adjustability of the array in space. The apparatus can be designed such that it is compatible with many navigation systems by making the connection at a distal end a universal type clamp. In another embodiment a fixed arm is provided in which the joints or hinges are eliminated. | 04-10-2014 |
20140099445 | METHOD FOR PRODUCING A FILM HAVING A NANO-STRUCTURE ON THE SURFACE OF THE FILM - A method is provided for producing easily a membrane (film) having a micro surface structure (porous structure, fibrous structure and the like) in nano-order. The method for producing a film having a nano-structure on the surface of the film, includes the steps of: (1) coating a substrate with a solution containing a copolymer including two or more homopolymer segments and an organic solvent having boiling point of 82° C. or more and a dielectric constant of 30 or less to form a membrane; (2) providing the membrane with a water vapor-containing gas having a relative humidity of 50% or more to age the membrane; and (3) drying the membrane to obtain the film. | 04-10-2014 |
20140090234 | APPARATUS AND METHODS FOR MULTI-SCALE ALIGNMENT AND FASTENING - Apparatus and methods for self-alignment and assembly of objects with micron-level and/or nanometer-level alignment accuracy. Mating alignment features spanning multiple length scales are disposed at surfaces of objects to be brought into contact. When the objects are pressed together, the alignment features guide alignment of the objects with respect to each other. The alignment features may provide retaining forces to hold the objects together. Micron-level and nanometer-level alignment accuracies may be achieved over large surface areas. | 04-03-2014 |
20140088270 | Mixed Organic and Inorganic Polymers - A polymer is characterized by a repeat unit represented by Structural Formula (I): | 03-27-2014 |
20140087451 | ACOUSTIC WAVE (AW) SENSING DEVICES USING LIVE CELLS - In one embodiment according to the invention, there is provided a method of sensing a response of a living cell or virus to a change in conditions. The method comprises applying an essentially constant external electromotive force that causes oscillation of an acoustic wave device at essentially constant amplitude and frequency under steady state conditions. The acoustic wave device has attached at least one living cell or virus. A combined oscillating system including the acoustic wave device and the living cell or virus exhibits a fundamental frequency and at least one harmonic frequency of the combined oscillating system. The living cell or virus is exposed to a change in an environmental condition while oscillating the combined oscillating system under the essentially constant external electromotive force, whereby a response of the living cell or virus to the change in environmental condition will be indicated by a change in at least one of frequency and amplitude of the oscillation of at least one harmonic frequency of the combined oscillating system. | 03-27-2014 |
20140086924 | COMPOUNDS THAT INHIBIT HSP90 PROTEIN-PROTEIN INTERACTIONS WITH IAP PROTEINS - Disclosed herein are compounds that inhibit Hsp90 interactions with IAP proteins, such as Survivin, XIAP, cIAP1, or cIAP2, and methods for identifying and using such compounds. | 03-27-2014 |
20140083869 | Detection Of Endotoxins - A complex comprises a polyene macrolide antibiotic and an endotoxin. Methods and devices detect the complex. A polymeric material functionalized with a polyene macrolide antibiotic is employed in the devices. | 03-27-2014 |
20140079712 | Therapeutic Applications Targeting SARM1 - The present disclosure provides methods for reducing axonal and/or synaptic degradation in neurons by modulating sterile α/Armadillo/Toll-Interleukin receptor homology domain protein (SARM) activity and/or expression. | 03-20-2014 |
20140072720 | PATTERNED NANOPARTICLE STRUCTURES - Aspects relate to patterned nanostructures having a feature size not including film thickness of below 5 microns. The patterned nanostructures are made up of nanoparticles having an average particle size of less than 100 nm. A nanoparticle composition, which, in some cases, includes a binder material, is applied to a substrate. A patterned mold used in concert with electromagnetic radiation function to manipulate the nanoparticle composition in forming the patterned nanostructure. In some embodiments, the patterned mold nanoimprints a suitable pattern on to the nanoparticle composition and the composition is cured through UV or thermal energy. Three-dimensional patterned nanostructures may be formed. A number of patterned nanostructure layers may be prepared and suitably joined together. In some cases, a patterned nanostructure may be formed as a layer that is releasable from the substrate upon which it is initially formed. Such releasable layers may, in turn, be arranged to form a three-dimensional patterned nanostructure in accordance with suitable applications. | 03-13-2014 |
20140066492 | SPINAL MUSCULAR ATROPHY (SMA) TREATMENT VIA TARGETING OF SMN2 SPLICE SITE INHIBITORY SEQUENCES - The present invention is directed to methods and compositions capable of blocking the inhibitory effect of a newly-identified intronic inhibitory sequence element, named ISS-N1 (for “intronic splicing silencer”), located in the SMN2 gene. The compositions and methods of the instant invention include oligonucleotide reagents (e.g., oligoribonucleotides) that effectively target the SMN2 ISS-N1 site in the SMN2 pre-mRNA, thereby modulating the splicing of SMN2 pre-mRNA to include exon 7 in the processed transcript. The ISS-N1 blocking agents of the invention cause elevated expression of SMN protein, thus compensating for the loss of SMN protein expression commonly observed in subjects with spinal muscular atrophy (SMA). | 03-06-2014 |
20140065425 | GRAFT-COPOLYMER STABILIZED METAL NANOPARTICLES - There is provided a method of preparing nanoparticles and novel nanoparticles. The nanoparticle preparation comprises the generation of a mixture comprising a plurality of metal-containing compounds and a copolymer of a polyethylene glycol and an amine-containing polyamino acid such as polylysine where a metal core and polymer shell nanoparticle is formed. The novel nanoparticles have a metallic core and a graft copolymer shell of polyethylene glycol and an amine-containing polyamino acid where the shell least partially surrounds the metallic core and is non-ionically bound to the metallic core via metal-amine bonds. | 03-06-2014 |
20140051979 | RELAXATION-CORRECTED ECG-TRIGGERING AND NAVIGATOR-GATING TECHNIQUE - A system and method for recording magnetic resonance images with reduced relaxation-related artifacts. The system and method improve the conventional methods for acquiring magnetic resonance images of in vivo tissue by augmenting the procedures for eliminating artifacts caused by motion with procedures for eliminating artifacts caused by spin of the magnetic resonance-active nuclei in the specimen of interest. One procedure to eliminate such spin inhomogeneities is to require a delay defined by the time N*T | 02-20-2014 |
20140045218 | HYDROPHILIC MODIFICATION OF WATER INSOLUBLE POLYSACCHARIDE AS SURFACE-ACTIVE AGENTS - A surfactant produced by reacting naturally occurring polysaccharides that are not water soluble with a hydrophilic substituent on a carboxylic portion of the polysaccharide. In a second reaction, the surfactant is further substituted on a hydroxylic portion with a hydrophobic or lipophilic substituent, so as to make the reaction product both water soluble and capable of attracting oily material that is hydrophobic to be removed from a substrate by cleaning in water. Methods of making the surfactant and the follow-on reaction product are described. | 02-13-2014 |
20140044722 | ANTI-SOD1 ANTIBODIES AND USES THEREOF - The present invention features anti-SOD1 antibodies and methods of using the antibodies for the treatment of amyotrophic lateral sclerosis (ALS) or the amelioration of symptoms associated with ALS. | 02-13-2014 |
20140039468 | SURGICAL CAVITY DRAINAGE AND CLOSURE SYSTEM - A surgical drain device includes an adhesion matrix of biodegradable polymer material and a plurality of drain tubes attached to the matrix. The device is implanted within a surgical wound to treat the presence of seromas, for example, and is used to promote drainage, tissue adhesion, and wound closure. The drain tubes converge into a common collection tube that leads wound fluid outside the body under gravity feed or negative pressure applied to the collection tube. The matrix contains an array of apertures that allow tissue contact across the device. The device also can include a coating of surgical adhesive and a tissue anchoring system of hooks or barbs. The device and systems containing the device are particularly useful to promote the healing of surgical wounds from abdominal surgery. | 02-06-2014 |
20130337472 | CELL DIVISION MARKER - This application relates to a newly identified animal cell structure, the midbody scar. This structure is a remnant of the midbody that is retained by one daughter cell following cytokinesis and persists through multiple subsequent cell cycles. The midbody scar can be useful as a marker of dividing cells or of a cell's replicative age. | 12-19-2013 |
20130331398 | MODULATION OF UBIQUITINATION OF SYNAPTIC PROTEINS FOR THE TREATMENT OF NEURODEGENERATIVE AND PSYCHIATRIC DISORDERS - The instant invention is based, at least in part, on a newly-identified proteasome-independent signaling function of ubiquitinated PSD-95. Mdm2 inhibitors, Mdm4 inhibitors, PSD-95 inhibitors, and/or enantiomers and/or derivatives thereof de-crease endocytosis via preventing PSD-95 ubiquitination, and thereby increase AMPAR, NMDAR, D1 dopamine receptor surface expression in response to a given stimulus (e.g., NMDA, Aβ). Accordingly, the invention provides methods for modulating AM-PARS, NMDARs, or D1 dopamine receptors in a neuronal cell by contacting the neuronal cell with an Mdm2 and/or Mdm4 inhibitor or PSD-95 inhibitor and/or enantiomers and/or derivatives thereof. Mdm2 and/or Mdm4 inhibitors decrease the enzymatic activity of the respective proteins, and/or interactions with their respective substrates. Mdm2 and Mdm4 inhibitors and/or PSD-95 inhibitors of the invention are contemplated for use in the treatment of neurological disorders, neurodevelopmental disorders, and psychiatric disorders. The invention also provides methods to screen for new Mdm2 and Mdm4 inhibitors and PSD-95 inhibitors and/or enantiomers and/or derivatives thereof. | 12-12-2013 |
20130324846 | DEVICES AND METHODS FOR OPTICAL PATHOLOGY - Currently most cancers, including breast cancers, are removed without any intraoperative margin control. Post-operative methods inspect 1-2% of the surgical margin and are prone to sampling errors. The present invention relates to an optical imaging system that will enable evaluation of the surgical margin in vivo and in real-time. The invention provides for simultaneous fluorescence and fluorescence polarization imaging. The contrast of the acquired images will be enhanced using fluorescent agents approved for diagnostic use in patients. As the staining pattern of fluorescence images is similar to that of histology, and the values of fluorescence polarization are significantly higher in cancerous as compared to normal cells, the invention provides for further improvements in diagnostic methods. The systems and methods can be applied to the intra-operative delineation of cancerous tissue. | 12-05-2013 |
20130324772 | METHOD FOR CONVERTING A HYDROCARBONACEOUS MATERIAL TO A FLUID HYDROCARBON PRODUCT COMPRISING P-XYLENE - The invention relates to a method for producing a fluid hydrocarbon product, and more specifically, to a method for producing a fluid hydrocarbon product via catalytic pyrolysis. The reactants comprise hydrocarbonaceous materials (e.g., biomass). The catalyst comprises a zeolite catalyst treated with a silicone compound. The product comprises p-xylene. | 12-05-2013 |
20130319123 | Photoacoustic Probe - A photoacoustic transducer, such as a photoacoustic probe includes an optical fiber, diaphragm, at the optical fiber, whereby the optical fiber and diaphragm define a cavity, and an energy absorption film at the optical fiber, whereby an activating laser directed through the optical fiber can excite the energy absorption film to thereby generate an acoustic wave that, upon reflection upon a remote surface, can deflect the diaphragm and modify reflection of a detecting laser also directed through the optical fiber. A method of detecting an acoustic wave includes directing an activating laser through an optical fiber to an energy absorption film at the optical fiber, directing a detecting laser through the optical fiber and cavity to the diaphragm at the optical fiber, and measuring an interference pattern generated at least in part by reflection of the detecting laser from a surface of the diaphragm. | 12-05-2013 |
20130310525 | INDUCED POLYMER ASSEMBLIES - The invention provides compositions and methods for inducing and enhancing order and nanostructures in block copolymers and surfactants by certain nonpolymeric additives, such as nanoparticles having an inorganic core and organic functional groups capable of hydrogen bonding. Various compositions having lattice order and nanostructures have been made from a variety of copolymers or surfactants that are mixed with nonpolymeric additives. Particularly, a variety of nanoparticles with an inorganic core and organic functional groups have been discovered to be effective in introducing or enhancing the degree of orders and nanostructures in diverse block copolymers and surfactants. | 11-21-2013 |
20130309767 | METHODS AND COMPOSITIONS FOR ENHANCING THE EFFICACY AND SPECIFICITY OF RNA SILENCING - The present invention provides methods of enhancing the efficacy and specificity of RNA silencing. The invention also provides compositions for mediating RNA silencing. In particular, the invention provides siRNAs, siRNA-like molecules, shRNAs, vectors and transgenes having improved specificity and efficacy in mediating silencing of a target gene. Therapeutic methods are also featured. | 11-21-2013 |
20130309206 | GYNOGENETIC OR ANDROGENETIC PRODUCTION OF PLURIPOTENT CELLS AND CELL LINES, AND USE THEREOF TO PRODUCE DIFFERENTIATED CELLS AND TISSUES - Methods for obtaining pluripotent (embryonic stem) cells from parthenogenetic embryos, especially primates, are provided. These cells are useful for producing differentiated cells, tissues and organs, especially human and non-human primate cells, tissues and organs. | 11-21-2013 |
20130287804 | IMMUNOGENIC POLYPEPTIDES HAVING AN IMMUNOGENIC SCAFFOLD PROTEIN AND A LOOP PEPTIDE, PRESENTING A 3074- OR 2219/2557- MONOCLONAL ANTIBODY-TARGETED EPITOPE, WHICH IS PRESENT IN THE HIV GP120 PROTEIN - The present invention is directed to a recombinant immunogenic polypeptide. The polypeptide includes a loop peptide inserted into an immunogenic scaffold protein. The loop polypeptide has an amino acid sequence which presents the 3074 mAb- or the 2219/2557 mAb-targeted epitope of the HIV gp120 protein and not other known epitopes of the HIV gp120 protein. When used as an immunogen, the polypeptide induces an antibody response which neutralizes heterologous HIV-1 viruses in a pattern similar to that observed for the 3074 mAb- or the 2219/2557 mAb-targeted epitope, respectively. Pharmaceutical compositions containing the immunogenic polypeptide as well as methods of making and using it are also disclosed. | 10-31-2013 |
20130280237 | PROTEIN TRANSDUCTION DOMAINS MIMICS - The invention generally relates to synthetic mimics of cell penetrating peptides. More particularly, the invention relates to certain novel monomers, oligomers and polymers (e.g., co-polymers) that are useful for the preparation of synthetic mimics of cell penetrating peptides, their compositions, preparations and use. | 10-24-2013 |
20130224793 | MODIFIED T7-RELATED RNA POLYMERASES AND METHODS OF USE THEREOF - The invention relates to modified T7-related RNA polymerases and methods of use thereof. In some embodiments, the invention relates to modified T7-related RNA polymerases that transcribe RNA with reduced abortive cycling and increased efficiency compared with native T7-related RNA polymerases. | 08-29-2013 |
20130217685 | COMPOUNDS FOR MODULATING RNA BINDING PROTEINS AND USES THEREFOR - The invention relates to compositions and methods for inhibiting RNA binding proteins (e.g., MEX-3, MEX-5 and POS-1), as well as methods for treating and preventing disorders associated with parasitic infections and inflammatory disorders. | 08-22-2013 |
20130198875 | RNA SEQUENCE-SPECIFIC MEDIATORS OF RNA INTERFERENCE - The present invention relates to a | 08-01-2013 |
20130195801 | CNS TARGETING AAV VECTORS AND METHODS OF USE THEREOF - The invention in some aspects relates to recombinant adeno-associated viruses useful for targeting transgenes to CNS tissue, and compositions comprising the same, and methods of use thereof. In some aspects, the invention provides methods and compositions for treating CNS-related disorders. | 08-01-2013 |
20130190409 | DRUG DELIVERY VEHICLES, METHODS OF MANUFACTURE, AND METHODS OF USE THEREOF - Drug delivery vehicles that release one or more drugs, e.g., an opioid antagonist and/or an opioid, in response to changes in the chemistry of body fluids, specifically in response to changes in the partial pressure of CO | 07-25-2013 |
20130174286 | In Vivo Gene Silencing By Chemically Modified and Stable siRNA - The present invention provides compositions for RNA interference and methods of use thereof. In particular, the invention provides small interfering RNAs (siRNAs) having modification that enhance the stability of the siRNA without a concomitant loss in the ability of the siRNA to participate in RNA interference (RNAi). The invention also provides siRNAs having modification that increase targeting efficiency. Modifications include chemical crosslinking between the two complementary strands of an siRNA and chemical modification of a 3′ terminus of a strand of an siRNA. Preferred modifications are internal modifications, for example, sugar modification, nucleobase modification and/or backbone modifications. Such modifications are also useful, e.g., to improve uptake of the siRNA by a cell. Functional and genomic and proteomic methods are featured. Therapeutic methods are also featured. | 07-04-2013 |
20130164774 | METHODS, COMPOSITIONS AND KITS FOR ASSAYING MITOCHONDRIAL FUNCTION - The invention provides methods, compositions, devices, and kits relating to the use of cholesterol-dependent cytolysins (e.g., PFOs) for measuring intracellular mitochondrial activity. | 06-27-2013 |
20130158217 | POLYMERIZATION INITIATING SYSTEM AND METHOD TO PRODUCE HIGHLY REACTIVE OLEFIN FUNCTIONAL POLYMERS - A method for producing highly reactive olefin polymers wherein at least 50 mol. % of the polymer chains have terminal double bonds, and a novel polymerization initiating system for accomplishing same. | 06-20-2013 |
20130158100 | INTRACELLULAR DNA RECEPTOR - Provided herein are methods of identifying and using compounds that modulate an AIM2 polypeptide-mediated immune response. Further provided herein are methods of treating disease comprising administering to a patient a compound that decreases expression of an AIM2 polypeptide. Further provided herein are methods of providing gene therapy to a patient comprising administering to the patient a gene therapy agent and a compound that decreases expression of an AIM2 polypeptide. In certain embodiments, a compound that decreases expression of an AIM2 polypeptide comprises an siRNA or an shRNA. | 06-20-2013 |
20130125259 | RNA INTERFERENCE MEDIATING SMALL RNA MOLECULES - Double-stranded RNA (dsRNA) induces sequence-specific post-transcriptional gene silencing in many organisms by a process known as RNA interference (RNAi). Using a | 05-16-2013 |
20130102754 | DEOXYBENZOIN-DERIVED ANTI-FLAMMABLE POLYMERS - The invention provides novel flame-retardant polymers and materials, their synthesis and use. More particularly, the flame-retardant polymers are deoxybenzoin-derived polymers. | 04-25-2013 |
20130101558 | AAV-BASED TREATMENT OF CHOLESTEROL-RELATED DISORDERS - The invention in some aspects relates to methods and compositions for assessing the effectiveness of miRNA inhibitors. In other aspects of the invention, methods and compositions for treating cholesterol related disorders are provided. In one aspect of the invention, miRNA inhibitors against miR-122 and rAAV-based compositions comprising the same are provided. | 04-25-2013 |
20130096009 | METHODS OF IDENTIFYING INTERACTIONS BETWEEN GENOMIC LOCI - The disclosed Hi-C protocol can identify genomic loci that are spatially co-located in vivo. These spatial co-locations may include, but are not limited to, intrachromosomal interactions and/or interchromosomal interactions. Hi-C techniques may be applied to many different scales of interest. For example, on a large scale, Hi-C techniques can be used to identify long-range interactions between distant genomic loci. | 04-18-2013 |
20130070251 | Systems and Methods of Dual-Plane Digital Holographic Microscopy - An embodiment of the disclosed DHM system includes a light source configured to emit coherent optical waves, a first optical Fourier element configured to Fourier transform the optical waves from the object area, wherein the Fourier transform occurs at a Fourier plane and the optical waves from the object area includes directly transmitted waves and diffracted waves, a phase modulator at the Fourier plane configured to introduce a phase delay between the directly transmitted waves and the diffracted waves, a second optical Fourier element configured to receive the directly transmitted waves and the diffracted waves from the phase modulator and to inversely Fourier transform the directly transmitted waves and the diffracted waves to provide interfered optical waves, and at least one imaging device configured to record the interfered optical waves at two image planes to generate a first interferogram and a second interferogram. | 03-21-2013 |
20130066050 | CHLAMYDOMONAS INTRAFLAGELLAR TRANSPORT 88 (IFT-88) - The invention relates to various intraflagellar transport (IFT) polypeptides and the nucleic acids that encode them. The new IFT particle polypeptides and nucleic acids can be used in a variety of diagnostic, screening, and therapeutic methods. | 03-14-2013 |
20130065941 | COMPOSITIONS AND THEIR USES FOR GENE THERAPY OF BONE CONDITIONS - In certain preferred embodiments, the present invention provides compositions and methods for the treatment of bone conditions associated with low bone density. In preferred embodiments, the present invention provides compositions and methods for the treatment of osteoprotegerin-responsive conditions. | 03-14-2013 |
20130060070 | METHOD FOR PRODUCING FLUID HYDROCARBONS - The invention relates to methods for producing fluid hydrocarbon products, and more specifically, to methods for producing fluid hydrocarbon product via catalytic pyrolysis. The reactants comprise solid hydrocarbonaceous materials, and hydrogen or a source of hydrogen (e.g., an alcohol). The products may include specific aromatic compounds (e.g., benzene, toluene, naphthalene, xylene, etc.). | 03-07-2013 |
20130040887 | Inhibiting Collagen-Induced Platelet Aggregation and Activation with Peptide Variants - The present invention provides peptides consisting of L- and/or D-amino acids and combinations thereof, which affect platelets by action on the collagen receptor, glycoprotein VI (GPVI). More specifically, however, the peptides act on the GPVI-FcRγ signaling complex. The invention also provides lipid and sugar conjugated peptides comprising L- or D-amino acids. The invention still further provides a method of designing of the peptides and lipid- and/or sugar-conjugated peptides comprising L- or D-amino acids. The present invention further relates to the therapy of various disease states involving the use of these peptides and compounds. Specifically, the peptides and compounds are useful in the treatment and/or prevention of a disease or condition involving platelet activation and aggregation, and more particularly, collagen-induced platelet activation and aggregation. They also are useful in the production of medical devices comprising peptide matrices (i.e., for example, cardiovascular stents). | 02-14-2013 |
20130039926 | HUMAN ANTIBODIES AGAINST RABIES AND USES THEREOF - Human monoclonal antibodies that specifically bind to rabies virus, antigen binding portions thereof, and methods of making and using such antibodies and antigen binding portions thereof for treating rabies virus in a subject, are provided herein. | 02-14-2013 |
20130023706 | CATALYTIC PYROLYSIS OF SOLID BIOMASS AND RELATED BIOFUELS, AROMATIC, AND OLEFIN COMPOUNDS - This invention relates to compositions comprising fluid hydrocarbon products, and to methods for making fluid hydrocarbon products via catalytic pyrolysis. Some embodiments relate to methods for the production of specific aromatic products (e.g., benzene, toluene, naphthalene, xylene, etc.) via catalytic pyrolysis. Some such methods involve the use of a composition comprising a mixture of a solid hydrocarbonaceous material and a heterogeneous pyrolytic catalyst component. The methods described herein may also involve the use of specialized catalysts. For example, in some cases, zeolite catalysts may be used. | 01-24-2013 |
20120330368 | ZYGOMATIC ELEVATOR DEVICE AND METHODS - A surgical elevator device that can be used in the reduction of bone fractures, particularly facial bone fractures, and even more particularly zygomatic arch fractures. The elevator device enables accurate measurement of the depth of insertion of the device into tissue space and provides tactile control of fracture location and reduction. In one embodiment, the elevator device comprises a groove on an elevator element for receiving a bone structure. The groove can be formed by a pair of parallel ridges. A projection extending from the elevator provides a pivot point for applying a controlled force to the bone to reduce the fracture. A preferred embodiment further comprises a method of reducing a bone fracture, such as a zygomatic arch fracture. | 12-27-2012 |
20120328629 | Therapeutic Applications Targeting SARM1 - The present disclosure provides methods for reducing axonal and/or synaptic degradation in neurons by modulating sterile α/Armadillo/Toll-Interleukin receptor homology domain protein (SARM) activity and/or expression. | 12-27-2012 |
20120327953 | DYNAMIC ADVANCE RESERVATION WITH DELAYED ALLOCATION - A method of scheduling data transmissions from a source to a destination, includes the steps of: providing a communication system having a number of channels and a number of paths, each of the channels having a plurality of designated time slots; receiving two or more data transmission requests; provisioning the transmission of the data; receiving data corresponding to at least one of the two or more data transmission requests; waiting until an earliest requested start time T | 12-27-2012 |
20120322846 | METHODS AND COMPOSITIONS FOR ENHANCING THE EFFICACY AND SPECIFICITY OF SINGLE AND DOUBLE BLUNT-ENDED siRNA - The present invention provides methods of enhancing the efficacy and specificity of RNAi using single or double blunt-ended siRNA. The invention also provides single and double-blunt ended siRNA compositions, vectors, and transgenes containing the same for mediating silencing of a target gene. Therapeutic methods are also featured. | 12-20-2012 |
20120321854 | System For Producing Patterned Silicon Carbide Structures - A method of forming ceramic pattern structures of silicon carbide film includes depositing an electron-beam resist or a photo-resist onto a substrate. A portion of the resist is selectively removed from the substrate to form a resist pattern on the substrate. A film of pre-ceramic polymer that includes silicon and carbon is deposited onto the substrate and resist pattern and the pre-ceramic polymer film is cured. A portion of the cured pre-ceramic polymer film on the resist pattern is removed, thereby forming a pre-ceramic polymer pattern on the substrate. The pre-ceramic polymer pattern is then converted to a ceramic pattern. | 12-20-2012 |
20120301912 | METHODS, COMPOSITIONS AND KITS FOR ASSAYING MITOCHONDRIAL FUNCTION - The invention provides methods, compositions, devices, and kits relating to the use of cholesterol-dependent cytolysins (e.g., PFOs) for measuring intracellular mitochondrial activity. | 11-29-2012 |
20120288510 | HUMAN ANTIBODIES AGAINST HEPATITIS C VIRUS (HCV) AND USES THEREOF - Isolated human monoclonal antibodies which bind to hepatitis C virus (HCV), and related antibody-based compositions and molecules, are disclosed. The human antibodies can be produced in a transfectoma or in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, non-human transgenic animals, and hybridomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies. | 11-15-2012 |
20120288508 | ANTIBODIES AGAINST CLOSTRIDIUM DIFFICILE TOXINS AND USES THEREOF - Antibodies that specifically bind to toxins of | 11-15-2012 |
20120282435 | Nanostructured Silicon with Useful Thermoelectric Properties - The invention provides for a nanostructured silicon or holey silicon (HS) that has useful thermoelectric properties. The invention also provides for a device comprising the nanostructured silicon or HS. The HS can be placed between two electrodes and used for thermoelectric power generation or thermoelectric cooling. | 11-08-2012 |
20120276564 | Luciferins - Novel luciferins, methods of making luciferins, and uses of the same are disclosed. | 11-01-2012 |
20120270979 | BLEND COMPOSITION, FLEXIBLE TUBING MATERIAL AND METHOD OF MAKING THE BLEND - A composition includes a blend of (a) a multi-block copolymer including at least one block of an elastomeric polymer and at least one block of a first polymer including a chiral polymer having a stereo isomeric configuration; and (b) a second polymer including an anti-chiral polymer corresponding to the chiral polymer in (a), wherein the second polymer includes an opposite handed stereo isomeric configuration to the chiral polymer in (a); wherein the blend of the chiral polymer and the anti-chiral polymer form stereo complex sites. A flexible tubing material further includes the blend. In an embodiment, a method of making the blend material is also provided. | 10-25-2012 |
20120270206 | Systems and Methods for Analyzing Nucleic Acid Sequences - The invention relates to systems and methods for analyzing clinically relevant nucleic acid sequences. | 10-25-2012 |
20120259202 | RELAXATION-CORRECTED ECG-TRIGGERING AND NAVIGATOR-GATING TECHNIQUE - A system and method for recording magnetic resonance images with reduced relaxation-related artifacts. The system and method improve the conventional methods for acquiring magnetic resonance images of in vivo tissue by augmenting the procedures for eliminating artifacts caused by motion with procedures for eliminating artifacts caused by spin of the magnetic resonance-active nuclei in the specimen of interest. One procedure to eliminate such spin inhomogeneities is to require a delay defined by the time N*T | 10-11-2012 |
20120252750 | FORMULATIONS FOR REDUCING NEURONAL DEGENERATION - Nutriceutical and pharmaceutical formulations for treating neurodegenerative disorders such as Alzheimer's disease are provided. Nutriceutical formulations include two or more of folate, vitamin E, and acetyl-L-carnitine (ALCAR). Pharmaceutical formulations include two or more of 3-deaza-adenosine (DZA), N-acetyl-L-cysteine (NAC), and S-adenosylmethionine (SAM). | 10-04-2012 |
20120252123 | NUCLEIC ACID SILENCING SEQUENCES - The present invention features compositions and methods for introducing, into cells, nucleic acids whose expression results in chromosomal silencing. The nucleic acids are targeted to specific chromosomal regions where they subsequently reduce the expression of deleterious genes, or cause the death of deleterious cells. Where the nucleic acid sequence is a silencing sequence, it may encode an Xist RNA or other non-coding, silencing RNA. Accordingly, the present invention features, inter alia, nucleic acid constructs that include a transgene (e.g., a silencing sequence encoding an Xist RNA or other non-coding RNA that silences a segment of a chromosome); first and second sequences that direct insertion of the silencing sequence into a targeted chromosome; and, optionally, a selectable marker. | 10-04-2012 |
20120214861 | METHODS AND COMPOSITIONS FOR TREATING NEUROLOGICAL DISEASE - This invention relates to methods and compositions for treating neurological disease, and more particularly to methods of delivering iRNA agents to neural cells for the treatment of neurological diseases. | 08-23-2012 |
20120207819 | COMPOSITIONS AND METHODS FOR WOUND HEALING - The present invention is related to the field of wound healing or tissue regeneration due to disease (i.e., for example, cardiovascular diseases, osetoarthritic diseases, or diabetes). In particular, the present invention provides compositions and methods comprising molecules with linked α-gal epitopes for induction of recruitment of macrophages localized within or surrounding damaged tissue. The recruited macrophages recruit stem cells and promote the repair and regeneration of the treated injured tissue. In some embodiments, the present invention provides treatments for tissue repair in normal subjects and in subjects having impaired healing capabilities, such as diabetic and aged subjects. In some embodiments, the present invention provides treatments for injured tissues such as brain, peripheral nerve, heart muscle, skeletal muscle, cartilage, bone, gastrointestinal tract and dysfunctional endocrine tissues. | 08-16-2012 |
20120203042 | SYSTEMS AND PROCESSES FOR CATALYTIC PYROLYSIS OF BIOMASS AND HYDROCARBONACEOUS MATERIALS FOR PRODUCTION OF AROMATICS WITH OPTIONAL OLEFIN RECYCLE, AND CATALYSTS HAVING SELECTED PARTICLE SIZE FOR CATALYTIC PYROLYSIS - This invention relates to compositions and methods for fluid hydrocarbon product, and more specifically, to compositions and methods for fluid hydrocarbon product via catalytic pyrolysis. Some embodiments relate to methods for the production of specific aromatic products (e.g., benzene, toluene, naphthalene, xylene, etc.) via catalytic pyrolysis. Some such methods may involve the use of a composition comprising a mixture of a solid hydrocarbonaceous material and a heterogeneous pyrolytic catalyst component. In some embodiments, an olefin compound may be co-fed to the reactor and/or separated from a product stream and recycled to the reactor to improve yield and/or selectivity of certain products. The methods described herein may also involve the use of specialized catalysts. For example, in some cases, zeolite catalysts may be used. In some instances, the catalysts are characterized by particle sizes in certain identified ranges that can lead to improve yield and/or selectivity of certain products. | 08-09-2012 |
20120196338 | METHODS AND COMPOSITIONS FOR IMPROVING THE PRODUCTION OF PRODUCTS IN MICROORGANISMS - Methods and compositions are provided for improving the production of products, such as fuel products like ethanol, in microorganisms. In particular, methods and compositions are described for improving ethanol production utilizing genes identified in | 08-02-2012 |
20120195403 | TOMOSYNTHESIS IMAGING - Systems and methods for providing radiographic, stereoscopic and tomographic images of an object of interest. Examples of objects of interest are body parts of living beings, such as the human breast and the human chest. The apparatus includes a high-fluence rate x-ray source and a plurality of satellite x-ray sources operating at lower fluence rate than the high-fluence rate source. A controller controls the operation and locations of the sources, and the operation of a detector. The method provides procedures in which the operation of the high-fluence source and the satellite sources are individually controlled as to location and orientation relative to the object of interest. In some operations, one satellite source may be operating while another satellite source may be repositioning. By proper control, a reduced x-ray dose and reduced operating time can be attained, thereby improving image quality, patient care, and patient experience. | 08-02-2012 |
20120190731 | METHODS AND COMPOSITIONS TO REDUCE OXIDATIVE STRESS - The invention relates to therapeutic applications for compositions that reduce the level of oxidative stress on cells in vivo or in vitro. The invention describes methods for improving the therapeutic properties of stem cells. The invention also provides combination therapies that are useful to balance the oxidative microenvironment of cells in vivo or in vitro. | 07-26-2012 |
20120178791 | MODULATION OF HUMAN CYTOMEGALOVIRUS REPLICATION BY MICRO-RNA 132 (miR132), MICRO-RNA 145 (miR145) AND MICRO-RNA 212 (miR212) - The present invention related to miR145, miR132, miR212, and the genes or gene products regulated by these miRNAs. miR145 is downregulated in cells infected with HCMV. This downregulation modulates expression of miR145 target genes, including IRS-I. Transfection of cells with a miR145 agent, such as a miR145 mimetic, reduces HCMV replication and protein expression. miR132 and miR212 are upregulated in cells infected with HCMV. This upregulation modulates expression of miR132 and miR212 target genes, including MeCP2 and RICS. Transfection of cells with a miR132 and/or a miR212 antagonist reduces HCMV replication and protein expression. Accordingly, the invention provides methods of attenuating HCMV replication by modulating, for example, miR145, miR132, and/or miR212, and targets thereof. Also provided are methods of detecting an HCMV infection, and compositions and kits useful for attenuating HCMV replication. | 07-12-2012 |
20120171247 | NOVEL PROTEINS WITHIN THE TYPE E BOTULINUM NEUROTOXIN COMPLEX - The invention features a polypeptide complex synthesized by bacteria of the genus | 07-05-2012 |
20120165394 | SPINAL MUSCULAR ATROPHY (SMA) TREATMENT VIA TARGETING OF SMN2 SPLICE SITE INHIBITORY SEQUENCES - The present invention is directed to methods and compositions capable of blocking the inhibitory effect of a newly-identified intronic inhibitory sequence element, named ISS-N1 (for “intronic splicing silencer”), located in the SMN2 gene. The compositions and methods of the instant invention include oligonucleotide reagents (e.g., oligoribonucleotides) that effectively target the SMN2 ISS-N1 site in the SMN2 pre-mRNA, thereby modulating the splicing of SMN2 pre-mRNA to include exon 7 in the processed transcript. The ISS-N1 blocking agents of the invention cause elevated expression of SMN protein, thus compensating for the loss of SMN protein expression commonly observed in subjects with spinal muscular atrophy (SMA). | 06-28-2012 |
20120164544 | AEROBIC MICROBIAL FUEL CELL - An aerobic microbial fuel cell anode electrode, a fuel cell using the anode, and methods of use. An anode electrode having a conductive exterior surface and having sufficient porosity to allow a fuel-bearing liquid flowing in a cavity within the anode to escape and to supply fuel to a biologically active microbe film grown on the exterior of the anode is situated in the fuel cell. When operated in an aerobic environment, such as water, the anode and a cathode can supply electrical power to a load without the need for a semi-permeable membrane between the anode and the cathode. Several embodiments in which the anode electrode is machined from a graphite block or cylinder are described. Conditions for growing the biologically active film and for operating the fuel cell are described. | 06-28-2012 |
20120152812 | METHOD TO REDUCE SLUDGE GENERATION IN WASTEWATER TREATMENT SYSTEMS - The systems and methods described provide for reducing sludge generation, and thus sludge wasting and handling, by including an anaerobic completely stirred tank reactor (CSTR) as a bioreactor in a side-stream. The CSTR provides a significant simplification of side-stream treatment design, enhanced sludge minimization, and enhanced removal of nitrogen and phosphorous without the need to add organic carbon. The described systems and methods provide generation of biogas including both hydrogen and methane from the activated sludge system. The described systems and methods avoid complex reactor designs for nutrient removal. | 06-21-2012 |
20120146869 | Planar Ultrawideband Modular Antenna Array - A planar ultrawideband modular antenna for connection to a feed network. The antenna has a ground plane, and an array of antenna elements spaced from the ground plane, each antenna element comprising a pair of arms. A first fed arm is electrically coupled to the feed network. The grounded arm is directly electrically coupled to the ground plane. There are one or more conductors such as conductive vias electrically connecting the fed arm to the ground plane, and optionally there are one or more additional conductors electrically connecting the grounded arm to the ground plane. | 06-14-2012 |
20120144582 | CONVERTIBLE WHEELCHAIR - A convertible wheelchair having two self-propelling rear wheels and two front casters, electric controls for converting from a chair position to a reclined position by an electric actuator connected between a bottom panel of a frame and under a seat support, a backrest connected pivotally at intermediate points between sides of the frame, and a leg support pivotally connected to front corners of the frame and front ends of the seat support. The wheelchair may be secured adjacent to a bed by a mount disc on a center portion of the rear wheels enabling a user to safely convert the wheelchair to the reclined position by moving a switch of the electric controls. When reclined, the user may move over onto the bed without a caregiver's assistance, unless necessary. | 06-14-2012 |
20120141733 | Articles Including Surface Microfeatures and Methods for Forming Same - A method of forming a polymer film includes dispensing a substrate and coating the substrate with a composition that is curable using actinic radiation. In an example, the method further includes exposing the composition to actinic radiation in presence of an atmosphere including 1 vol % to 37 vol % oxygen, whereby the surface of the composition forms an undulating morphology. In another example, the method further includes applying an oxygen-containing overlay over the composition, exposing the composition to actinic radiation through the oxygen-containing overlay, and removing the oxygen-containing overlay, whereby the surface of the composition forms an undulating morphology. | 06-07-2012 |
20120136039 | SINGLE NUCLEOTIDE POLYMORPHISM (SNP) TARGETING THERAPIES FOR THE TREATMENT OF HUNTINGTON'S DISEASE - The present invention relates to the discovery of (SNPs) significantly associated with Huntington's disease (HD). The present invention utilizes RNA silencing technology (e.g. RNAi) against such SNPs optimally combined with select additional SNP targeting silencing agents, thereby resulting in an effective treatment of significantly-sized patient populations. Silencing agents having enhanced discriminatory properties are also featured. | 05-31-2012 |
20120100583 | Enzymatic Synthesis of Polymers - The invention relates to new methods of enzymatic synthesis of polymers such as polyorganosilicones and polyesters, and new polymers made by these methods. | 04-26-2012 |
20120097521 | NANOSTRUCTURED APPARATUS AND METHODS FOR PRODUCING CARBON-CONTAINING MOLECULES AS A RENEWABLE ENERGY RESOURCE - Nanostructured arrays having a metal catalyst (e.g., cobalt) are irradiated with light to initiate the an artificial photosynthetic reaction resulting in the formation of carbon-containing molecules, for example, long chained hydrocarbons or amino acids. A nanostructure having one or more structural elements having a high aspect ratio can formed over a substrate and are placed in contact with water and a carbon-containing source (e.g., carbon dioxide, bicarbonate, methane). When the nanostructure is exposed to light, the water and the carbon-containing source can react to form a molecule having at least two carbon atoms chained together. Structural elements may include a number of metal layers arranged in a patterned configuration so that, upon light irradiation, a greater amount of light energy is concentrated in close proximity to the region where the reaction is catalyzed than for the case without the patterned configuration. | 04-26-2012 |
20120094925 | INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 7 FOR TREATMENT OF CANCER - Methods of treating a tumor in a subject include identifying a subject having, at risk for, or suspected of having a tumor, and administering to the subject an effective amount of an IGFBP7 agent if the tumor has increased Ras-BRAF-MEK-Erk signaling, is dependent for growth and/or survival upon the Ras-BRAF-MEK-Erk signaling pathway, and/or expresses an activated or oncogenic BRAF or RAS. | 04-19-2012 |
20120076761 | Cloned ungulate embryos and animals, use of cells, tissues and organs thereof for transplantation therapies including Parkinson's disease - Methods and cell lines for cloning ungulate embryos and offspring, in particular bovines and porcines, are provided. The resultant fetuses, embryos or offspring are especially useful for the expression of desired heterologous DNAs, and may be used as a source of cells or tissue for transplantation therapy for the treatment of diseases such as Parkinson's disease. | 03-29-2012 |
20120070376 | YEAST CELL WALL PARTICLES FOR RECEPTOR-TARGETED NANOPARTICLE DELIVERY - The present invention generally relates to yeast cell wall microparticles loaded with nanoparticles for receptor-targeted nanoparticle delivery. In particular, the present invention relates to trapping nanoparticles either on the surface or inside a yeast glucan particles, for example, yeast glucal particles. The present invention further relates to methods of making the yeast cell wall particles loaded with nanoparticles. The present invention also relates to methods of using the yeast cell wall particles loaded with nanoparticles for receptor-targeted delivery of the nanoparticles, e.g., drug containing nanoparticles. | 03-22-2012 |
20120046448 | CHLAMYDOMONAS INTRAFLAGELLAR TRANSPORT 88 (IFT-88) - The invention relates to various intraflagellar transport (IFT) polypeptides and the nucleic acids that encode them. The new IFT particle polypeptides and nucleic acids can be used in a variety of diagnostic, screening, and therapeutic methods. | 02-23-2012 |
20120040444 | METHOD AND APPARATUS FOR PREPARING CELLS FOR MICROTOME SECTIONING AND ARCHIVING NUCLEIC ACIDS AND PROTEINS - A method and apparatus for embedding cells that utilizes a flow-through embedding technique. The apparatus includes a cell flow pathway defined by an inflow tube for delivering cell fragments from a cell sample to a sample port. The sample port is in fluid communication with a tissue cassette having attached thereto a filter. The cell flow pathway is in communication with a reagent flow pathway for delivering the reagents through the sample port to the cassette. The apparatus is configured such that the application of pressure directs the cell fragments from the cell sample through the cell flow pathway, and effects delivery of the reagents through the reagent flow pathway. The apparatus produces an embedded cell block having concentrated cells near the plane of the block to be sectioned in a quick and efficient manner. | 02-16-2012 |
20120039929 | NOVEL THERAPY FOR LYSOSOMAL ENZYME DEFICIENCIES - The present invention provides a therapeutic delivery system comprising an extracted yeast cell wall comprising beta-glucan, a payload trapping molecule and a payload molecule, wherein the payload molecule and the payload trapping molecule are soluble in the same solvent system wherein the payload molecule supplements the function of the deficient lysosomal enzyme. The invention further provides methods of making and methods of using the therapeutic delivery system. | 02-16-2012 |
20120034597 | METHODS OF MONITORING TREATMENT OF AVIREMIC HIV-INFECTED PATIENTS - Methods of monitoring the efficacy of intensified highly active anti-retroviral therapy (HAART) treatment in aviremic Human Immunodeficiency Virus (HIV)-infected patients. | 02-09-2012 |
20120022415 | MODULAR THERAPEUTIC PRESSURE APPLICATION DEVICES - The invention relates in some aspects to therapeutic pressure application devices and methods of manufacturing and using the same. In some aspects, the devices comprise a support structure shaped to conform to a portion of a body of an individual; a bladder having a port for the passage of a fluid, the bladder being supported by the support structure; a pump having a fluid outlet, the pump being secured to the support structure; and separable fluid connectors operably connecting the pump with the port. | 01-26-2012 |
20120015372 | METHODS AND COMPOSITIONS FOR PATHOGEN DETECTION USING FLUORESCENT POLYMER SENSORS - Compositions, methods and related apparatus, as can be used for selective pathogen detection and identification. | 01-19-2012 |
20110319570 | POLYESTERS WITH GRAFTED ZWITTERIONS - The invention relates to polymers, such as aliphatic polyesters, with grafted zwitterions. More particularly, the invention relates to polyester-graft-phosphorylcholine polymers prepared by ring-opening polymerization and click chemistry, compositions and products comprising same, and related methods and uses, for example, in drug delivery. | 12-29-2011 |
20110319569 | ZWITTERIONIC POLYMERS WITH THERAPEUTIC MOIETIES - The invention generally relates to zwitterionic polymers (including zwitterionic copolymers), such as polymethacrylic structures, with pendent functional moieties, such as therapeutic or biologic moieties. More particularly, the invention relates to phosphorylcholine-substituted methacrylic polymers prepared by free radical polymerization and click chemistry, for example, and compositions and products comprising same, as well as related methods and uses of the compositions, for example, as biological or therapeutic agents and in drug delivery thereof. | 12-29-2011 |
20110293653 | ANTAGONISTS OF MIR-155 FOR THE TREATMENT OF INFLAMMATORY LIVER DISEASE - Provided herein are methods of treating or preventing an inflammatory liver disease in a subject, such as alcoholic liver disease (ALD), by administering to said subject an miR-155 antagonist. | 12-01-2011 |
20110288238 | ENHANCED TRANSPORT USING MEMBRANE DISRUPTIVE AGENTS - Compositions and methods for transport or release of therapeutic and diagnostic agents or metabolites or other analytes from cells, compartments within cells, or through cell layers or barriers are described. The compositions include a membrane barrier transport enhancing agent and are usually administered in combination with an enhancer and/or exposure to stimuli to effect disruption or altered permeability, transport or release. In a preferred embodiment, the compositions include compounds which disrupt endosomal membranes in response to the low pH in the endosomes but which are relatively inactive toward cell membranes, coupled directly or indirectly to a therapeutic or diagnostic agent. Other disruptive agents can also be used, responsive to stimuli and/or enhancers other than pH, such as light, electrical stimuli, electromagnetic stimuli, ultrasound, temperature, or combinations thereof. The compounds can be coupled by ionic, covalent or H bonds to an agent to be delivered or to a ligand which forms a complex with the agent to be delivered. Agents to be delivered can be therapeutic and/or diagnostic agents. Treatments which enhance delivery such as ultrasound, iontopheresis, and/or electrophoresis can also be used with the disrupting agents. | 11-24-2011 |
20110286930 | METHODS OF IDENTIFYING MODULATORS OF THE PP2A B56 BETA REGULATORY SUBUNIT - The present invention is based at least in part on the discovery that the PP2A B56 regulatory subunit plays a role in regulating insulin signaling by directly regulating phosphorylation of AKT-I. Accordingly, the present invention features methods of identifying modulators of the PP2A B56 regulatory subunit in assays featuring organisms and/or cells. Further featured are therapeutic methods for the use of PP2A B56 regulatory subunit modulators to enhance longevity, to prevent or treat cancer, to prevent or reduce obesity and to prevent or treat type II diabetes. | 11-24-2011 |
20110275933 | MOTION COMPENSATION IN NUCLEAR IMAGING - The invention relates to methods and systems for compensating for respiratory motion of individuals during nuclear imaging. In some embodiments, the methods include obtaining data representing a reference respiratory state for the individual and obtaining data that represents a plurality of respiratory states that correspond to at least a portion of a cycle of respiration of the individual; comparing each of the plurality of respiratory states to a subset of the reference state data to obtain a motion estimate of each of the plurality of respiratory states; compensating for respiratory motion in each of the plurality of respiratory states based on the motion estimates to obtain motion-compensated respiratory state data; and constructing an image using the motion-compensated respiratory state data. | 11-10-2011 |
20110245554 | Production of Hydrogen, Liquid Fuels, and Chemicals from Catalytic Processing of Bio-Oils - Disclosed herein is a method of generating hydrogen from a bio-oil, comprising hydrogenating a water-soluble fraction of the bio-oil with hydrogen in the presence of a hydrogenation catalyst, and reforming the water-soluble fraction by aqueous-phase reforming in the presence of a reforming catalyst, wherein hydrogen is generated by the reforming, and the amount of hydrogen generated is greater than that consumed by the hydrogenating. The method can further comprise hydrocracking or hydrotreating a lignin fraction of the bio-oil with hydrogen in the presence of a hydrocracking catalyst wherein the lignin fraction of bio-oil is obtained as a water-insoluble fraction from aqueous extraction of bio-oil. The hydrogen used in the hydrogenating and in the hydrocracking or hydrotreating can be generated by reforming the water-soluble fraction of bio-oil. | 10-06-2011 |
20110229522 | METHODS, COMPOSITIONS AND VACCINES RELATING TO NEISSERIA MENINGITIDIS ANTIBODIES - The invention provides compositions and methods for screening subjects at risk for contracting meningococcal disease and/or at risk for failing to elicit an immunogenic response to a vaccine against | 09-22-2011 |
20110212022 | ANTITUMOR ANTIBODIES, PROTEINS, AND USES THEREOF - Antibodies that bind to a 40 kDa protein which is expressed on tumors, but is not expressed on normal adult hemopoietic cells are disclosed. Also disclosed are methods for production and the use of such antibodies. | 09-01-2011 |
20110207659 | OLIGOSACCHARIDE COMPOSITIONS AND USE THEREOF IN THE TREATMENT OF INFECTION - Oligosaccharides and oligosaccharides linked to backbones such as proteins, methods for making such oligosaccharides and methods for using them to treat and/or prevent various disorders are described. | 08-25-2011 |
20110207224 | IN VIVO PRODUCTION OF SMALL INTERFERING RNAS THAT MEDIATE GENE SILENCING - The invention provides engineered RNA precursors that when expressed in a cell are processed by the cell to produce targeted small interfering RNAs (siRNAs) that selectively silence targeted genes (by cleaving specific mRNAs) using the cell's own RNA interference (RNAi) pathway. By introducing nucleic acid molecules that encode these engineered RNA precursors into cells in vitro with appropriate regulatory sequences, expression of the engineered RNA precursors can be selectively controlled both temporally and spatially, i.e., at particular times and/or in particular tissues, organs, or cells. | 08-25-2011 |
20110206739 | COMPOSITIONS AND METHODS FOR THE PREPARATION OF NANOEMULSIONS - The disclosure relates to compositions and methods of forming nanoemulsions, e.g., containing an active component, in combination with lipophilic components such as oils, hydrophilic components such as water, and one or more surfactants capable of causing a temperature-dependent phase inversion, such as a nonionic polyethoxylated surfactant. Nanoemulsions containing the active component can be produced having average oil droplet sizes of less than 100 nm, 50 nm, or 25 nm without the need for high energy emulsion forming methods (such as microfluidization) by combining the surfactant and the oil in specified weight ratios (e.g., at least 3:1) prior to forming the nanoemulsion. | 08-25-2011 |
20110205535 | SPECTROSCOPIC SENSORS - Disclosed herein are sensors that include: (a) a circuit board that includes an electronic processor; (b) a plurality of radiation sources, each source being attached to the circuit board; and (c) a spectral detector attached to the circuit board, the spectral detector being configured to analyze radiation derived from one or more of the plurality of radiation sources. During use, the sensors are configured to be worn on a portion of a body of a subject. The electronic processor is configured to cause two or more of the plurality of radiation sources to direct incident radiation to the subject, to cause the spectral detector to analyze radiation from the subject, and to determine one or more properties of the subject based on the radiation from the subject. Methods of making and using these sensors are also disclosed. | 08-25-2011 |
20110200675 | DRUG DELIVERY VEHICLES, METHODS OF MANUFACTURE, AND METHODS OF USE THEREOF - Drug delivery vehicles that release one or more drugs, e.g., an opioid antagonist and/or an opioid, in response to changes in the chemistry of body fluids, specifically in response to changes in the partial pressure of CO | 08-18-2011 |
20110178046 | Methods for Treating Glioblastoma - Described are methods for treating cancers, e.g., glioblastoma, including administering an inhibitor of Notch signalling, e.g., a gamma secretase inhibitor, in combination with a chemotherapeutic agent. | 07-21-2011 |
20110172291 | RNA INTERFERENCE FOR THE TREATMENT OF GAIN-OF-FUNCTION DISORDERS - The present invention relates to the discovery of an effective treatment for a variety of gain-of-function diseases, in particular, Huntington's disease (HD). The present invention utilizes RNA Interference technology (RNAi) against polymorphic regions in the genes encoding various gain-of-function mutant proteins resulting in an effective treatment for the gain-of-function disease. | 07-14-2011 |
20110171258 | POLYVALENT, PRIMARY HIV-1 GLYCOPROTEIN DNA VACCINES AND VACCINATION METHODS - Polyvalent, primary isolate nucleic acid compositions for inducing an immune response against HIV is disclosed. The compositions and methods described herein are for the use of a DNA composition that encodes one or more different HIV envelope glycoproteins. The DNA composition can encode an HIV Gag protein. The DNAs encoding one or more HIV proteins are a combination of different nucleic acids, such as DNA plasmids, generated from primary isolate DNA of different HIV major group genetic clades and/or different proteins. HIV protein compositions for inducing an immune response against HIV are disclosed. Methods for using the protein compositions as boosts following administration of the DNA compositions are provided. | 07-14-2011 |
20110165683 | CHIMERIC GAMMARETROVIRUS - The invention is directed to a chimeric gammaretrovirus comprising an gammaretroviral virion which contains a lentiviral Vpx protein and methods of use thereof. | 07-07-2011 |
20110165616 | METHOD AND APPARATUS FOR BIOPSY SAMPLE PROCESSING - A container for use in processing a biopsy sample. Biopsy sample and materials are received within a sample processing area of the container. A semi-permeable barrier is positioned at a downstream portion of the sample processing area and prevents the prevent passage of the biopsy sample. A cap is positioned at the downstream side of the barrier, and holds fluids within the container. | 07-07-2011 |
20110160286 | ALLELE-SPECIFIC RNA INTERFERENCE - Human diseases caused by dominant, gain-of-function mutations develop in heterozygotes bearing one mutant and one wild-type copy of a gene. Because the wild-type gene often performs important functions, whereas the mutant gene is toxic, any therapeutic strategy must selectively inhibit the mutant while retaining wild-type gene expression. The present invention includes methods of specifically inhibiting the expression of a mutant allele, while preserving the expression of a co-expressed wild-type allele using RNAi, a therapeutic strategy for treating genetic disorders associated with dominant, gain-of-function gene mutations. The invention also includes small interfering RNAs (siRNAs) and small hairpin RNAs (shRNAs) that selectively suppress mutant, but not wild-type, expression of copper zinc superoxide dismutase (SOD1), which causes inherited amyotrophic lateral sclerosis (ALS). The present invention further provides asymmetric siRNAs and shRNAs with enhanced efficacy and specificity and mediating RNAi. | 06-30-2011 |
20110158913 | Antisense and pretargeting optical imaging - The present invention relates, in part, to detectably labeled oligomer duplexes and their use in optical imaging, including, in vivo optical imaging. The invention includes methods of optical imaging including in vivo pretargeting methods and in vivo antisense optical imaging methods. | 06-30-2011 |
20110152347 | Methods and compositions for controlling efficacy of RNA silencing - Based at least in part on an understanding of the mechanisms by which small RNAs (e.g., naturally-occurring miRNAs) mediate RNA silencing in plants, rules have been established for determining, for example, the degree of complementarity required between an RNAi-mediating agent and its target, i.e., whether mismatches are tolerated, the number of mismatches tolerated, the effect of the position of the mismatches, etc. Such rules are useful, in particular, in the design of improved RNAi-mediating agents which allow for more exact control of the efficacy of RNA silencing. | 06-23-2011 |
20110152251 | COMPOUNDS FOR MODULATING TLR2 - The present invention is directed to methods, kits, and uses of inhibitors of LCMV mediated NF-κB activation to treat viral infections and inflammatory conditions. | 06-23-2011 |
20110151544 | Geobacter Strains That Use Alternate Organic Compounds, Methods of Making, and Methods of Use Thereof - In preferred embodiments, the present invention provides new isolated strains of a | 06-23-2011 |
20110151430 | VIRUS-SPECIFIC miRNA SIGNATURES FOR DIAGNOSIS AND THERAPEUTIC TREATMENT OF VIRAL INFECTION - The present invention related to miRNA signatures and diagnostic and therapeutic applications of miRNA signatures. The miRNA signatures are defined by a test sample miRNA profile relative to an appropriate control miRNA profile. In some embodiments, the test sample is a sample isolated, obtained or derived from a virus-infected cell or organism. The present invention further relates to the use of miRNA signatures in the identification of druggable targets and antiviral agents. Kits and compositions are also provided. | 06-23-2011 |
20110117573 | CELL DIVISION MARKER - This application relates to a newly identified animal cell structure, the midbody scar. This structure is a remnant of the midbody that is retained by one daughter cell following cytokinesis and persists through multiple subsequent cell cycles. The midbody scar can be useful as a marker of dividing cells or of a cell's replicative age. | 05-19-2011 |
20110086048 | DETECTION OF HUMAN IMMUNODEFICIENCY VIRUS CO-RECEPTOR TROPISM IN AVIREMIC SUBJECTS - Methods for detecting human immunodeficiency virus (HIV) co-receptor tropism or replication-competent virus in aviremic subjects, and methods of selecting optimal therapies for aviremic subjects. | 04-14-2011 |
20110081664 | MULTIPURPOSE MICROFLUIDIC DEVICE FOR MIMICKING A MICROENVIRONMENT WITHIN A TUMOR - The present application relates generally to a novel microfluidic device for the in it propagation of neoplastic cellagregates under conditions that mimic the physiological microenvironment found in tumors. The invention also describes methods of screening for therapeutic test agents and protocols that target proliferating and quiescent neoplastic cells within tumors. | 04-07-2011 |
20110072626 | NOVEL FABRIC FINISHING METHODS AND FABRICS - This invention provides methods for finishing knitted fabrics and fabrics finished by the novel process. In one embodiment, the method of finishing a knitted fabric includes the steps of: (a) stretching the fabric above about 5% but less than about 25% in width, and above about (−)7% but less than about 10% in length, (b) heat-setting the fabric to the stretched width and length at a temperature above about 120 degrees Centigrade and lowefthan about 250 degrees Centigrade, and (c) applying a polymeric protective binder coating resin to the fabric at a concentration of at least 5% but less than 25% based on the weight of the fabric. | 03-31-2011 |
20110059086 | ESPFU NUCLEIC ACIDS AND PROTEINS AND USES THEREOF - Disclosed are EspF | 03-10-2011 |
20110027394 | Cross-Linked Biopolymers, Related Compounds and Methods of Use - The present invention provides stabilized oil-in-water emulsions with an extended range of chemical, thermal and/or mechanical stabilities, and method(s) for their preparation. Such preparations provide an environmentally-protective biopolymer component exhibiting improved adherence to the dispersed phase, reducing or eliminating dissociation therefrom under such conditions, for use in the context of a range of food, pharmaceutical, personal care, health care, cosmetic and other end-use applications. | 02-03-2011 |
20110020227 | POLYSACCHARIDE-CONTAINING BLOCK COPOLMER PARTICLES AND USES THEREOF - The invention relates to new amphiphilic linear block copolymers of polysaccharides and polymers. The amphiphilic linear block copolymers do not form a true solution in water and are able to form micelles in selective solvents. Also disclosed are particles, each of which has a shell and a core, and a diameter of about 1 to 1,000 nanometers, and methods of delivering agents or removing substances, e.g., undesirable substances, from a subject or environment, by using these particles. | 01-27-2011 |
20110008360 | HUMAN ANTIBODIES AGAINST RABIES AND USES THEREOF - Human monoclonal antibodies that specifically bind to rabies virus, antigen binding portions thereof, and methods of making and using such antibodies and antigen binding portions thereof for treating rabies virus in a subject, are provided herein. | 01-13-2011 |
20100330340 | SUPERHYDROPHOBIC SURFACES FOR DRAG REDUCTION - Superhydrophobic surfaces according to the invention contain micro or nanoscale hydrophobic features which can support a shear-free air-water interface between peaks in the surface topology. The surface of an engineered structure is patterned with a plurality of parallel ridges extending from the surface. The ridges have a width d and a height h, and are spaced apart by a first spacing dimension w. The ridges extend along the surface of the solid object for a predefined length l. Breaker ridges are situated between the parallel ridges, and are oriented at an angle to the parallel ridges. The breaker ridges are preferably spaced apart by a second spacing dimension. The breaker ridges and the parallel ridges are configured to define a volume wherein a gas may be situated. The engineered structure is configured to provide a reduced drag force between itself and a fluid. | 12-30-2010 |
20100317105 | Methods and compositions for controlling efficacy of RNA silencing - Based at least in part on an understanding of the mechanisms by which small RNAs (e.g., naturally-occurring miRNAs) mediate RNA silencing in plants, rules have been established for determining, for example, the degree of complementarity required between an RNAi-mediating agent and its target, i.e., whether mismatches are tolerated, the number of mismatches tolerated, the effect of the position of the mismatches, etc. Such rules are useful, in particular, in the design of improved RNAi-mediating agents which allow for more exact control of the efficacy of RNA silencing. | 12-16-2010 |
20100310647 | Enzymatic Synthesis of Polymers - The invention relates to new methods of enzymatic synthesis of polymers such as polyorganosilicones and polyesters, and new polymers made by these methods. | 12-09-2010 |
20100304189 | GEOBACTERACEAE STRAINS AND METHODS - Embodiments of the present invention provide a method of producing genetically modified strains of electricigenic microbes that are specifically adapted for the production of electrical current in microbial fuel cells, as well as strains produced by such methods and fuel cells using such strains. In preferred embodiments, the present invention provides genetically modified strains of | 12-02-2010 |
20100303817 | ANTIBODIES TO TREAT CANCER - Compositions and methods for the treatment of cancer, particularly melanoma, myeloma, small cell lung cancer, thymic lymphoma, T-cell lymphoma, B-cell lymphoma, osteosarcoma, and acute T-cell leukemia, are disclosed. Illustrative compositions include one or more anti-ganglioside antibodies and polynucleotides that encode such anti-ganglioside antibodies. These antibodies may be for example, hamster antibodies, chimeric human/hamster antibodies, or humanized antibodies. The disclosed compositions are useful, for example, in the treatment of cancer and can be used to induce apoptosis in a cancer cell. | 12-02-2010 |
20100291577 | Toll-Like Receptor 9 Modulators - TLR9 is localized to endoplasmic reticulum and upon stimulation with a TLR9 ligand, is transported to a tubular lysosomal compartment as is CpG-DNA. Furthermore, it is shown that TLR9 and CpG-DNA directly bind. It was also found that the MyD88 translocates in response to activation of TLR9-mediated signaling. Methods of identifying compounds that affect translocation and activity of TLR9 and MyD88 are described. | 11-18-2010 |
20100291550 | Methods and compositions for modulating hair growth - The invention relates, in part, to methods and compounds that are useful to modulate hair growth in mammals. The invention, in part, also includes nucleic acids, polypeptides, and genetic constructs that may be used to diagnose and treat hair growth disorders, for screening for compounds that modulate hair growth, and for selecting treatment regimens for subjects with hair loss disorders or hair growth conditions. The invention in some aspects also includes kits that may include polypeptides and/or nucleic acids for diagnosis of hair growth disorders and/or for the modulation of hair growth in subjects. | 11-18-2010 |
20100286304 | POLYMERIC COMPOSITIONS, METHODS OF MANUFACTURE THEREOF AND ARTICLES COMPRISING THE SAME - Disclosed herein is a polymeric composition comprising a polymeric composition comprising a first crosslinked network; and a second crosslinked network; wherein the first crosslinked network is crosslinked at a first stress and/or a first strain and the second crosslinked network is crosslinked at a second stress and/or a second strain; where the first stress and/or the first strain is different from the second stress and/or the second strain either in magnitude or direction. Disclosed herein is a method comprising subjecting a polymeric mass to a first stress and/or a first strain level; crosslinking the polymeric mass to form a first crosslinked network; subjecting the polymeric mass to a second stress and/or a second strain level; and crosslinking the polymeric mass to form a second crosslinked network; where the first stress and/or the first strain level is different from the second stress and/or the second strain level. | 11-11-2010 |
20100282977 | SPECT CAMERA - Systems and methods for providing improved detectors for use in SPECT cameras. The improved detectors use pinhole apertures and surfaces calculated to provide improved sensitivity and resolution. In some embodiments, the detectors have non-planar surfaces. In some embodiments, the surfaces are spherical, conical, parabolic, or other non-planar forms. | 11-11-2010 |
20100281087 | APPROXIMATE SRT DIVISION METHOD - The invention relates to a program storage device readable by a machine, tangibly embodying a program of instructions executable by a specific semiconductor-based computational device situated in the machine to perform the steps of a partial SRT (PSRT) division of a dividend X by a divisor D to obtain a quotient Q. The steps include: causing a computer to obtain the dividend X and the divisor D; representing the dividend X and the divisor D as a digital representation having a plurality of bits; and performing iteratively a series of steps until a desired accuracy of the quotient Q is achieved. The invention also relates to an article of manufacture including a computer usable medium having computer readable program code embodied therein for causing a partial SRT (PSRT) division of a dividend X by a divisor D to generate a quotient Q. | 11-04-2010 |
20100268691 | Universal Visualization Platform - The invention relates to a framework system and methods for connecting a plurality of tools. The system comprises a plug-in mechanism configured to dynamically load the plurality of tools, a data pool having storage space configured to store data sets associated with the plurality of tools, a linking mechanism configured to establish communications links between the loaded plurality of tools to enable coordinated operation of the loaded plurality of tools, a session component configured to record the process history of the operations of the loaded plurality of tool and the system states corresponding to the process history of the operations and an annotation module configured to associate user-provided data corresponding to one or more of the stored data sets. | 10-21-2010 |
20100267810 | METHODS AND COMPOSITIONS FOR TREATING NEUROLOGICAL DISEASE - This invention relates to methods and compositions for treating neurological disease, and more particularly to methods of delivering iRNA agents to neural cells for the treatment of neurological diseases. | 10-21-2010 |
20100249022 | STRATEGY FOR CLONING AND EXPRESSING THE EXTRACELLULAR DOMAINS OF RECEPTORS AS SOLUBLE PROTEINS - The present invention relates generally to soluble G protein-coupled receptor constructs. More specifically, the invention relates to soluble chemokine receptors, and soluble HIV co-receptors in particular. The invention is generally useful for designing and constructing soluble GPCR, which may be used to identify binding molecules. The invention also relates to methods of treating and/or preventing a disease or disorder associated with impaired function of such a receptor. The invention thus provides compositions and methods for therapeutic applications, such as vaccine. | 09-30-2010 |
20100245694 | Systems and Methods of All-Optical Fourier Phase Contrast Imaging Using Dye Doped Liquid Crystals - An assembly for converting a microscope into a phase contrast microscope includes a first optical Fourier element that Fourier transforms light from a coherent light source, a cell in the Fourier plane arranged to receive light from the first optical Fourier element, a second optical Fourier element arranged to receive light from the cell and inversely Fourier transform the received light to provide an image, an image sensor that detects the image and generates an electronic representation of the image, and an adaptor capable of coupling the first and second Fourier elements, the cell, and the image sensor to the microscope such that the first Fourier element Fourier transforms light collected by the microscope objective. The cell includes liquid crystal molecules having a phase transition temperature, wherein at temperatures exceeding the phase transition temperature, light transmitting through the liquid crystal molecules obtains a different phase than light transmitting through the liquid crystal molecules at temperatures below the phase transition temperature. | 09-30-2010 |
20100234448 | IN VIVO PRODUCTION OF SMALL INTERFERING RNAS THAT MEDIATE GENE SILENCING - The invention provides engineered RNA precursors that when expressed in a cell are processed by the cell to produce targeted small interfering RNAs (siRNAs) that selectively silence targeted genes (by cleaving specific mRNAs) using the cell's own RNA interference (RNAi) pathway. By introducing nucleic acid molecules that encode these engineered RNA precursors into cells in vivo with appropriate regulatory sequences, expression of the engineered RNA precursors can be selectively controlled both temporally and spatially, i.e., at particular times and/or in particular tissues, organs, or cells. | 09-16-2010 |
20100233810 | IN VIVO PRODUCTION OF SMALL INTERFERING RNAS THAT MEDIATE GENE SILENCING - The invention provides engineered RNA precursors that when expressed in a cell are processed by the cell to produce targeted small interfering RNAs (siRNAs) that selectively silence targeted genes (by cleaving specific mRNAs) using the cell's own RNA interference (RNAi) pathway. By introducing nucleic acid molecules that encode these engineered RNA precursors into cells in vivo with appropriate regulatory sequences, expression of the engineered RNA precursors can be selectively controlled both temporally and spatially, i.e., at particular times and/or in particular tissues, organs, or cells. | 09-16-2010 |
20100233182 | Antibodies against Clostridium difficile toxins and uses thereof - Antibodies that specifically bind to toxins of | 09-16-2010 |
20100233181 | ANTIBODIES AGAINST CLOSTRIDIUM DIFFICILE TOXINS AND USES THEREOF - Antibodies that specifically bind to toxins of | 09-16-2010 |
20100221743 | Methods for Diagnosing and Treating Endoplasmic Reticulum (ER) Stress Diseases - The present invention provides methods and reagents to quantify endoplasmic reticulum stress (ER stress) levels, and methods and compounds for treating ER stress disorders such as diabetes. Methods for quantifying ER stress in mammalian cells are exemplified. | 09-02-2010 |
20100221357 | DRUG DELIVERY PRODUCT AND METHODS - The present invention provides a particulate delivery system comprising an extracted yeast cell wall comprising beta-glucan, a payload molecule and a payload trapping molecule. The invention further provides methods of making and methods of using the particulate delivery system. | 09-02-2010 |
20100215665 | MIXED LINEAGE KINASES AND METABOLIC DISORDERS - Methods of treating metabolic stress disorders are disclosed that include administering to a subject a therapeutically effective amount of a composition that specifically inhibits the expression or activity of a mixed lineage kinase (MLK). Also disclosed are methods of identifying candidate compounds for treatment of metabolic stress disorders and methods of diagnosing metabolic stress disorders. | 08-26-2010 |
20100211066 | Use of IMP3 as a Prognostic Marker for Cancer - Provided herein are methods and compositions for the prognostic evaluation of a patient suspected of having, or having, cancer by assessing the expression of IMP3 in a biological sample of a patient. Methods can be used at the time of initial diagnosis of malignant tumors to identify a group of patients with a high potential to develop progression or metastasis later. Therefore, methods not only are able to provide very useful prognostic information for patients but also can help clinicians to select a candidate patient likely to benefit from early and aggressive cancer therapy. Methods and compositions for the treatment of cancer associated with expression of IMP3 are also provided. | 08-19-2010 |
20100210711 | Methods and Compositions for the Treatment of Sterile Inflammation - Described are methods and compositions that inhibit IL-1 signalling for the treatment of acute inflammatory response to cell necrosis, and the attendant collateral tissue damage. | 08-19-2010 |
20100186103 | Isolation Of Novel AAV'S And Uses Thereof - The invention in some aspects relates to isolated nucleic acids, compositions, and kits useful for identifying adeno-associated viruses in cells. In some aspects, the invention provides kits and methods for producing somatic transgenic animal models using recombinant AAV (rAAV) to an animal having at least one transgene that expresses a small interfering nucleic acid or at least one binding site for a miRNA. | 07-22-2010 |
20100184828 | METHODS AND COMPOSITIONS FOR ENHANCING THE EFFICACY AND SPECIFICITY OF RNA SILENCING - The present invention provides methods of enhancing the efficacy and specificity of RNA silencing. The invention also provides compositions for mediating RNA silencing. In particular, the invention provides siRNAs, siRNA-like molecules, shRNAs, vectors and transgenes having improved specificity and efficacy in mediating silencing of a target gene. Therapeutic methods are also featured. | 07-22-2010 |
20100184827 | METHODS AND COMPOSITIONS FOR ENHANCING THE EFFICACY AND SPECIFICITY OF RNA SILENCING - The present invention provides methods of enhancing the efficacy and specificity of RNA silencing. The invention also provides compositions for mediating RNA silencing. In particular, the invention provides siRNAs, siRNA-like molecules, shRNAs, vectors and transgenes having improved specificity and efficacy in mediating silencing of a target gene. Therapeutic methods are also featured. | 07-22-2010 |
20100184826 | METHODS AND COMPOSITIONS FOR ENHANCING THE EFFICACY AND SPECIFICITY OF RNA SILENCING - The present invention provides methods of enhancing the efficacy and specificity of RNA silencing. The invention also provides compositions for mediating RNA silencing. In particular, the invention provides siRNAs, siRNA-like molecules, shRNAs, vectors and transgenes having improved specificity and efficacy in mediating silencing of a target gene. Therapeutic methods are also featured. | 07-22-2010 |